Fuse Oncology, Inc.
AI NativeCare at the speed of the patient
Est 2021|Raised $11.8M
Published Sep 19, 2026
| Starting Price | Not publicly posted (quote-based) | Not publicly posted (enterprise quote-based) | Not publicly posted (enterprise quote-based) |
| Best For | Organizations seeking a workflow overlay for charge capture oversight, documentation assistance, and operational analytics | Organizations requiring a treatment delivery–integrated OIS aligned with the Varian ecosystem | Organizations using the Elekta ecosystem needing an OIS and oncology informatics functionality |
| Key Strength | Modular tooling focused on charge capture auditing and documentation workflows as described by the vendor; designed to interoperate with existing systems | Deep integration with Varian treatment delivery workflows and broad installed base | Established OIS footprint and integrations; recognized in historical sector evaluations |
| Key Weakness | Limited independent third-party review density in public sources; some ROI and security claims lack public validation; potential integration complexity | Can be complex and costly to customize and operate at scale | User community has raised usability and data access concerns in public forums |
—
Areas where Fuse may provide differentiation:
Areas where incumbents typically have advantages:
Market adoption signals: